These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 20551532)
1. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test. Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532 [TBL] [Abstract][Full Text] [Related]
2. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. Oliveira AD; D'Azevedo PA; Francisco W Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812 [TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804 [TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates. Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082 [TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740 [TBL] [Abstract][Full Text] [Related]
7. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Scoper SV Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691 [TBL] [Abstract][Full Text] [Related]
8. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fluoroquinolones against common respiratory pathogens. Aydemir S; Tunger A; Cilli F West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812 [TBL] [Abstract][Full Text] [Related]
10. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363 [TBL] [Abstract][Full Text] [Related]
11. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
13. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051 [TBL] [Abstract][Full Text] [Related]
14. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567 [TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296 [TBL] [Abstract][Full Text] [Related]
16. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487 [TBL] [Abstract][Full Text] [Related]